These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

200 related articles for article (PubMed ID: 32555695)

  • 1. Prognostic factors for changes in the timed 4-stair climb in patients with Duchenne muscular dystrophy, and implications for measuring drug efficacy: A multi-institutional collaboration.
    Goemans N; Wong B; Van den Hauwe M; Signorovitch J; Sajeev G; Cox D; Landry J; Jenkins M; Dieye I; Yao Z; Hossain I; Ward SJ;
    PLoS One; 2020; 15(6):e0232870. PubMed ID: 32555695
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Individualized Prediction of Changes in 6-Minute Walk Distance for Patients with Duchenne Muscular Dystrophy.
    Goemans N; Vanden Hauwe M; Signorovitch J; Swallow E; Song J;
    PLoS One; 2016; 11(10):e0164684. PubMed ID: 27737016
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Natural History of Steroid-Treated Young Boys With Duchenne Muscular Dystrophy Using the NSAA, 100m, and Timed Functional Tests.
    Miller NF; Alfano LN; Iammarino MA; Connolly AM; Moore-Clingenpeel M; Powers BR; Tsao CY; Waldrop MA; Flanigan KM; Mendell JR; Lowes LP
    Pediatr Neurol; 2020 Dec; 113():15-20. PubMed ID: 32979653
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Meaningful changes in motor function in Duchenne muscular dystrophy (DMD): A multi-center study.
    Muntoni F; Signorovitch J; Sajeev G; Done N; Yao Z; Goemans N; McDonald C; Mercuri E; Niks EH; Wong B; Vandenborne K; Straub V; de Groot IJM; Tian C; Manzur A; Dieye I; Lane H; Ward SJ; Servais L; ; ; ; ;
    PLoS One; 2024; 19(7):e0304984. PubMed ID: 38985784
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tamoxifen in Duchenne muscular dystrophy (TAMDMD): study protocol for a multicenter, randomized, placebo-controlled, double-blind phase 3 trial.
    Nagy S; Hafner P; Schmidt S; Rubino-Nacht D; Schädelin S; Bieri O; Fischer D
    Trials; 2019 Nov; 20(1):637. PubMed ID: 31752977
    [TBL] [Abstract][Full Text] [Related]  

  • 6.
    Muntoni F; Signorovitch J; Sajeev G; Lane H; Jenkins M; Dieye I; Ward SJ; McDonald C; Goemans N; Niks EH; Wong B; Servais L; Straub V; Guglieri M; de Groot IJM; Chesshyre M; Tian C; Manzur AY; Mercuri E; Aartsma-Rus A;
    Neurology; 2023 Apr; 100(15):e1540-e1554. PubMed ID: 36725339
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A phase 3 randomized placebo-controlled trial of tadalafil for Duchenne muscular dystrophy.
    Victor RG; Sweeney HL; Finkel R; McDonald CM; Byrne B; Eagle M; Goemans N; Vandenborne K; Dubrovsky AL; Topaloglu H; Miceli MC; Furlong P; Landry J; Elashoff R; Cox D;
    Neurology; 2017 Oct; 89(17):1811-1820. PubMed ID: 28972192
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Knee Strength and Ankle Range of Motion Impacts on Timed Function Tests in Duchenne Muscular Dystrophy: In the Era of Glucocorticoids.
    Duong T; Canbek J; Fernandez-Fernandez A; Henricson E; Birkmeier M; Siener C; Tesi Rocha C; McDonald C; Gordish-Dressman H;
    J Neuromuscul Dis; 2022; 9(1):147-159. PubMed ID: 34719507
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Suitability of external controls for drug evaluation in Duchenne muscular dystrophy.
    Goemans N; Signorovitch J; Sajeev G; Yao Z; Gordish-Dressman H; McDonald CM; Vandenborne K; Miller D; Ward SJ; Mercuri E;
    Neurology; 2020 Sep; 95(10):e1381-e1391. PubMed ID: 32611643
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Stride Velocity 95th Centile Detects Decline in Ambulatory Function Over Shorter Intervals than the 6-Minute Walk Test or North Star Ambulatory Assessment in Duchenne Muscular Dystrophy.
    Rabbia M; Guridi Ormazabal M; Staunton H; Veenstra K; Eggenspieler D; Annoussamy M; Servais L; Strijbos P
    J Neuromuscul Dis; 2024; 11(3):701-714. PubMed ID: 38640165
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Randomized phase 2 trial and open-label extension of domagrozumab in Duchenne muscular dystrophy.
    Wagner KR; Abdel-Hamid HZ; Mah JK; Campbell C; Guglieri M; Muntoni F; Takeshima Y; McDonald CM; Kostera-Pruszczyk A; Karachunski P; Butterfield RJ; Mercuri E; Fiorillo C; Bertini ES; Tian C; Statland J; Sadosky AB; Purohit VS; Sherlock SP; Palmer JP; Binks M; Charnas L; Marraffino S; Wong BL
    Neuromuscul Disord; 2020 Jun; 30(6):492-502. PubMed ID: 32522498
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy and safety of vamorolone in Duchenne muscular dystrophy: An 18-month interim analysis of a non-randomized open-label extension study.
    Smith EC; Conklin LS; Hoffman EP; Clemens PR; Mah JK; Finkel RS; Guglieri M; Tulinius M; Nevo Y; Ryan MM; Webster R; Castro D; Kuntz NL; Kerchner L; Morgenroth LP; Arrieta A; Shimony M; Jaros M; Shale P; Gordish-Dressman H; Hagerty L; Dang UJ; Damsker JM; Schwartz BD; Mengle-Gaw LJ; McDonald CM;
    PLoS Med; 2020 Sep; 17(9):e1003222. PubMed ID: 32956407
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Treatment with L-citrulline and metformin in Duchenne muscular dystrophy: study protocol for a single-centre, randomised, placebo-controlled trial.
    Hafner P; Bonati U; Rubino D; Gocheva V; Zumbrunn T; Gueven N; Fischer D
    Trials; 2016 Aug; 17(1):389. PubMed ID: 27488051
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The Minimal Clinical Important Difference (MCID) in Annual Rate of Change of Timed Function Tests in Boys with DMD.
    Duong T; Canbek J; Birkmeier M; Nelson L; Siener C; Fernandez-Fernandez A; Henricson E; McDonald CM; Gordish-Dressman H;
    J Neuromuscul Dis; 2021; 8(6):939-948. PubMed ID: 34151852
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Categorizing natural history trajectories of ambulatory function measured by the 6-minute walk distance in patients with Duchenne muscular dystrophy.
    Mercuri E; Signorovitch JE; Swallow E; Song J; Ward SJ; ;
    Neuromuscul Disord; 2016 Sep; 26(9):576-83. PubMed ID: 27423700
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Participation in daily life activities and its relationship to strength and functional measures in boys with Duchenne muscular dystrophy.
    Bendixen RM; Lott DJ; Senesac C; Mathur S; Vandenborne K
    Disabil Rehabil; 2014; 36(22):1918-23. PubMed ID: 24499260
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Glucocorticoid corticosteroids for Duchenne muscular dystrophy.
    Manzur AY; Kuntzer T; Pike M; Swan A
    Cochrane Database Syst Rev; 2008 Jan; (1):CD003725. PubMed ID: 18254031
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The 100-meter timed test: Normative data in healthy males and comparative pilot outcome data for use in Duchenne muscular dystrophy clinical trials.
    Alfano LN; Miller NF; Berry KM; Yin H; Rolf KE; Flanigan KM; Mendell JR; Lowes LP
    Neuromuscul Disord; 2017 May; 27(5):452-457. PubMed ID: 28279570
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy and Safety of Vamorolone in Duchenne Muscular Dystrophy: A 30-Month Nonrandomized Controlled Open-Label Extension Trial.
    Mah JK; Clemens PR; Guglieri M; Smith EC; Finkel RS; Tulinius M; Nevo Y; Ryan MM; Webster R; Castro D; Kuntz NL; McDonald CM; Damsker JM; Schwartz BD; Mengle-Gaw LJ; Jackowski S; Stimpson G; Ridout DA; Ayyar-Gupta V; Baranello G; Manzur AY; Muntoni F; Gordish-Dressman H; Leinonen M; Ward LM; Hoffman EP; Dang UJ;
    JAMA Netw Open; 2022 Jan; 5(1):e2144178. PubMed ID: 35076703
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Glucocorticoid corticosteroids for Duchenne muscular dystrophy.
    Manzur AY; Kuntzer T; Pike M; Swan A
    Cochrane Database Syst Rev; 2004; (2):CD003725. PubMed ID: 15106215
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.